6ge2
From Proteopedia
(Difference between revisions)
m (Protected "6ge2" [edit=sysop:move=sysop]) |
|||
| (2 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==exendin-4 based dual GLP-1/glucagon receptor agonist== | |
| + | <StructureSection load='6ge2' size='340' side='right'caption='[[6ge2]]' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[6ge2]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Heloderma_suspectum Heloderma suspectum]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6GE2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6GE2 FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR, 10 models</td></tr> | ||
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=AIB:ALPHA-AMINOISOBUTYRIC+ACID'>AIB</scene>, <scene name='pdbligand=EVT:(2~{S})-2-[[(4~{S})-4-(hexadecanoylamino)-5-oxidanyl-5-oxidanylidene-pentanoyl]amino]pentanedioic+acid'>EVT</scene>, <scene name='pdbligand=NH2:AMINO+GROUP'>NH2</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6ge2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ge2 OCA], [https://pdbe.org/6ge2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6ge2 RCSB], [https://www.ebi.ac.uk/pdbsum/6ge2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6ge2 ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | == Function == | ||
| + | [https://www.uniprot.org/uniprot/EXE4_HELSU EXE4_HELSU] Venom protein that mimics the incretin hormone glucagon-like peptide 1 (GLP-1). It stimulates insulin synthesis and secretion, protects against beta-cell apoptosis in response to different insults, and promotes beta-cell proliferation. It also promotes satiety, reduces food intake, reduces fat deposition, reduces body weight and inhibits gastric emptying. Interacts with GLP-1 receptor (GLP1R). Induces hypotension that is mediated by relaxation of cardiac smooth muscle.<ref>PMID:8405712</ref> <ref>PMID:19837656</ref> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Novel peptidic dual agonists of the glucagon-like peptide 1 (GLP-1) and glucagon receptor are reported to have enhanced efficacy over pure GLP-1 receptor agonists with regard to treatment of obesity and diabetes. We describe novel exendin-4 based dual agonists designed with an activity ratio favoring the GLP-1 versus the glucagon receptor. As result of an iterative optimization procedure that included molecular modeling, structural biological studies (X-ray, NMR), peptide design & synthesis, experimental activity and solubility profiling, a candidate molecule was identified. Novel SAR points are reported that allowed to fine-tune the desired receptor activity ratio and increased solubility in the presence of antimicrobial preservatives - findings which can be of general applicability for any peptide discovery project. The peptide was evaluated in chronic in vivo studies in obese diabetic monkeys as translational model for the human situation and demonstrated favorable blood glucose and body weight lowering effects. | ||
| - | + | Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multi-dose Formulations.,Evers A, Bossart M, Pfeiffer-Marek S, Elvert R, Schreuder HA, Kurz M, Stengelin S, Lorenz M, Herling A, Konkar AA, Lukasczyk U, Pfenninger A, Lorenz K, Haack T, Kadereit D, Wagner M J Med Chem. 2018 Jun 7. doi: 10.1021/acs.jmedchem.8b00292. PMID:29879354<ref>PMID:29879354</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | [[Category: | + | </div> |
| - | [[Category: | + | <div class="pdbe-citations 6ge2" style="background-color:#fffaf0;"></div> |
| - | [[Category: Evers | + | == References == |
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Heloderma suspectum]] | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Evers A]] | ||
| + | [[Category: Kurz M]] | ||
Current revision
exendin-4 based dual GLP-1/glucagon receptor agonist
| |||||||||||
